{"title":"[Overview of practices among French clinical pathologists specialized in haemostasis].","authors":"Andréas Perrier-Cornet, Nicolas Gendron, Céline Desconclois, Virginie Planche, Caroline Vayne, Fabienne Nedelec Gac, Cécile Lavenu-Bombled, Dominique Lasne, Claire Flaujac, Myriam Hormi","doi":"10.1684/abc.2025.1959","DOIUrl":null,"url":null,"abstract":"<p><p>Medical biology is a medical specialty shared by medical doctor (MD) and pharmacists (PharmD), and Hemostasis is one of its disciplines. Since 2007, physicians have lost interest in medical biology. In haemostasis, the regulatory heterogeneity of status between medical biologists/MDs and medical biologists/PharmDs in a strained health system raises two major issues: (i) with demographic change, optimal patient care may no longer be guaranteed, (ii) medical biologists/PharmDs are sometimes forced to go beyond the scope of their regulatory field of practice. We conducted a survey in 2022 to examine hemostasis advice and consultation practices: 152 professionals responded, including 99 pharmacist-biologists (65.1%), 42 physician-biologists (27.6%) and 11 clinicians (7.2%). Of the practitioners questioned, 91.9% gave diagnostic advice and 75.0% therapeutic advice. 41% of respondents carried out haemostasis consultations, including 24.2% of pharmacists. Our survey reveals a little-known role for medical biologists specialized in haemostasis, particularly pharmacists, and calls for a global reflection on a possible regulated and supervised evolution of their field of practice, to enable them to pursue their mission in complete safety.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 2","pages":"147-60"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1684/abc.2025.1959","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Medical biology is a medical specialty shared by medical doctor (MD) and pharmacists (PharmD), and Hemostasis is one of its disciplines. Since 2007, physicians have lost interest in medical biology. In haemostasis, the regulatory heterogeneity of status between medical biologists/MDs and medical biologists/PharmDs in a strained health system raises two major issues: (i) with demographic change, optimal patient care may no longer be guaranteed, (ii) medical biologists/PharmDs are sometimes forced to go beyond the scope of their regulatory field of practice. We conducted a survey in 2022 to examine hemostasis advice and consultation practices: 152 professionals responded, including 99 pharmacist-biologists (65.1%), 42 physician-biologists (27.6%) and 11 clinicians (7.2%). Of the practitioners questioned, 91.9% gave diagnostic advice and 75.0% therapeutic advice. 41% of respondents carried out haemostasis consultations, including 24.2% of pharmacists. Our survey reveals a little-known role for medical biologists specialized in haemostasis, particularly pharmacists, and calls for a global reflection on a possible regulated and supervised evolution of their field of practice, to enable them to pursue their mission in complete safety.